A multi-method valuation combining DCF, relative multiples, and Monte Carlo simulation to derive a probability-weighted fair value estimate.
Base Free Cash Flow: $9.08B (FY2025) yielding $1.59 per share on 5.71B diluted shares. This represents a 14.5% FCF margin, down from COVID peaks but above pre-pandemic norms. The FCF conversion supports the going-concern assumption underlying terminal value.
Growth Phases: Years 1-3 assume 8% revenue growth as Seagen integration delivers $3B+ incremental oncology revenue and COVID comparables ease. Years 4-7 taper to 4% as patent expirations (Eliquis 2027, Ibrance 2027) create headwinds. The 8% near-term assumption is aggressive versus -1.6% FY2025 revenue growth but supported by Q4 2025 implied revenue of $17.57B showing sequential stabilization.
Terminal Growth Rate (3.0%): This assumes Pfizer maintains position-based competitive advantages—specifically economies of scale in oncology commercialization and customer captivity through prescriber relationships—that sustain excess returns above WACC in perpetuity. This is justified for a top-three global pharma with Seagen's ADC platform providing durable differentiation, though subject to mean-reversion risk if R&D productivity remains below industry norms.
WACC Components: Cost of equity at 6.9% (4.25% risk-free + 0.48 beta × 5.5% equity risk premium) reflects Pfizer's defensive beta post-COVID normalization. After-tax cost of debt at ~4.5% and market-cap-based D/E of 0.41 yields blended WACC of 6.1%. The 0.48 beta is below sector average of ~0.65, capturing reduced earnings volatility but potentially understating pipeline binary risk.
Margin Sustainability Assessment: Current 74.3% gross margin and 12.4% net margin are modeled to recover toward 76% and 15% respectively as oncology mix improves and SG&A scales from 22.0% toward 20%. This assumes successful capability-based competitive advantage from Seagen integration; failure to achieve $1B+ synergies would force mean-reversion to 70% gross, 10% net industry averages.
Market-Implied Expectations: At $26.58, the market prices Pfizer for perpetual decline. The reverse DCF calculation yields an implied growth rate of -12.3% assuming 6.1% WACC, or alternatively an implied WACC of 8.7% assuming 3.0% terminal growth. Both interpretations are inconsistent with observed fundamentals.
The Disconnect: Quarterly revenue data shows stabilization—Q1-Q4 2025 progression of $13.71B → $14.65B → $16.65B → $17.57B (implied)—directly contradicting expectations of -12% annual decline. This suggests either: (a) market-implied WACC of 8.7% reflects appropriate risk premium for pipeline binary outcomes, or (b) market prices near-term earnings collapse that quarterly data has not yet captured.
Implied FCF Margin: The current price implies terminal FCF margin of ~8% versus 14.5% realized in FY2025, suggesting market expects 550bps of permanent margin compression. This would require gross margin falling to 68% (from 74.3%) and net margin to 7% (from 12.4%), levels last seen during pre-COVID restructuring.
Reasonableness Assessment: The -12.3% implied growth is unreasonable if Seagen integration proceeds as planned and COVID revenue has troughed. However, it becomes reasonable if: (a) Eliquis faces early generic entry in 2026, (b) Seagen pipeline disappoints, or (c) IRA pricing pressure exceeds 25% discounts. The 8.7% implied WACC is more defensible, reflecting 200bps premium to model WACC for execution risk on $71.26B goodwill-heavy balance sheet.
Conclusion: The reverse DCF suggests market skepticism about management's execution capability rather than fundamental deterioration. The $26.58 price is consistent with fair value if WACC is 8.7% and growth is 0-1%, not the 6.1%/3.0% base case. This 200bps WACC differential explains the $30.89 gap between DCF fair value and market price.
| parameter | value |
|---|---|
| revenue (base) | $62.6b (usd) |
| fcf margin | 14.5% |
| wacc | 6.1% |
| terminal growth | 3.0% |
| growth path | -1.7% → 0.1% → 1.2% → 2.1% → 3.0% |
| template | general |
| method | fair value | vs current | key assumption | confidence |
|---|---|---|---|---|
| dcf base case | $57.90 | +114.7% | 3.0% terminal growth, 6.1% wacc | MEDIUM |
| dcf bull case | $139.38 | +416.8% | seagen synergies + pipeline success | LOW |
| dcf bear case | $26.59 | -1.4% | patent cliff + integration failure | MEDIUM |
| monte carlo median | $16.30 | -39.6% | 10,000 simulations, wide distribution | HIGH |
| monte carlo mean | $30.89 | +14.5% | right-skewed distribution | HIGH |
| reverse dcf (implied) | $26.97 | +0.0% | -12.3% implied growth, 8.7% wacc | HIGH |
| company | p/e | p/s | rev growth | net margin | fcf yield |
|---|---|---|---|---|---|
| pfizer (pfe) | 19.5x | 2.4x | -1.6% | 12.4% | 6.0% |
| assumption | base value | break value | price impact | break probability |
|---|---|---|---|---|
| seagen synergies | $1.0b+ | $0.5b | -$12 | MEDIUM 25% |
| terminal growth rate | 3.0% | 1.5% | -$18 | MEDIUM 30% |
| wacc | 6.1% | 8.0% | -$22 | MEDIUM 20% |
| eliquis patent cliff | 2027 expiration | 2026 early entry | -$8 | LOW 15% |
| goodwill impairment | $0 | $10b | -$15 | MEDIUM 20% |
| ira price negotiation | minimal impact | -15% on $15b | -$10 | MEDIUM 35% |
| implied parameter | value to justify current price |
|---|---|
| implied growth rate | -12.3% |
| implied wacc | 8.7% |
| component | value |
|---|---|
| beta | 0.48 (raw: 0.41, vasicek-adjusted) |
| risk-free rate | 4.25% |
| equity risk premium | 5.5% |
| cost of equity | 6.9% |
| d/e ratio (market-cap) | 0.41 |
| dynamic wacc | 6.1% |
| metric | value |
|---|---|
| current growth rate | -6.5% |
| growth uncertainty | ±28.1pp |
| observations | 5 |
| year 1 projected | -6.5% |
| year 2 projected | -6.5% |
| year 3 projected | -6.5% |
| year 4 projected | -6.5% |
| year 5 projected | -6.5% |